Enhancing Psoriasis Care: The Role of Biosimilars Enhancing Psoriasis Care: The Role of Biosimilars
Dr Steven Feldman shares key insights and practical tips about biosimilars in psoriasis management.Medscape Dermatology (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 18, 2023 Category: Dermatology Tags: Dermatology Commentary Source Type: news
BIMZELX[ ®] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis
18 OCTOBER 2023 – 07:00 (CEST) – Regulated Information – Inside Information – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis in adults who…#ucb #fda #il17a #vivid #todaysfda #bimzelx #emmanuelcaeymaex #immunologysolutions #il17f #marklebwohl (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2023 Category: Consumer Health News Source Type: news
Evelo hits new low as psoriasis flop sparks hunt for alternative
Evelo Biosciences’ last roll of the dice has come up snake eyes. After seeing its lead candidate flounder in the clinic, the biotech has revealed its next-generation asset performed worse than placebo in a phase 2 psoriasis trial, prompting it to start searching for strategic alternatives. The…#evelobiosciences #flagshipventures #evelo (Source: Reuters: Health)
Source: Reuters: Health - October 17, 2023 Category: Consumer Health News Source Type: news
Patients With Psoriasis Lose Weight With Roflumilast: Study Patients With Psoriasis Lose Weight With Roflumilast: Study
Oral roflumilast not only appears to improve skin symptoms, but it could also help with weight loss, results of the phase 2 PSORRO study suggest.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 13, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
COVID Might Raise Odds for Immune Disorders Like Crohn's, Alopecia
TUESDAY, Oct. 10, 2023 -- In rare cases, some patients may develop an autoimmune disease following a bout of COVID, Korean researchers report.
Conditions such as alopecia (hair loss), psoriasis, vitiligo (white skin patches), vasculitis... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 10, 2023 Category: General Medicine Source Type: news
Mayo Clinic Minute: Psoriasis of the scalp
Psoriasis, a skin condition affecting 2% to 3% of the population, can appear in various areas, including the scalp. Symptoms can range from mild to severe, causing uncomfortable flare-ups marked by itchiness. Dr. Dawn Davis, a dermatologist at Mayo Clinic, says psoriasis is a multisystem inflammatory disorder primarily affecting the skin. She says psoriasis is inherited, and more people might have genes that make them more likely to develop the condition. Learn more about psoriasis of… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 10, 2023 Category: Databases & Libraries Source Type: news
Palmoplantar Psoriasis More Common Among Black Children Palmoplantar Psoriasis More Common Among Black Children
The prevalence of nail, palm, and sole involvement was highest among Black children with psoriasis compared with children of other ethnicities.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 9, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
FDA Approves Arcutis ’ Zoryve (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
WESTLAKE VILLAGE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE)— Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 6, 2023 Category: Drugs & Pharmacology Source Type: news
FDA OKs Topical Roflumilast for Psoriasis in Kids Aged 6-11 FDA OKs Topical Roflumilast for Psoriasis in Kids Aged 6-11
This marks an expanded indication for the drug, which was first approved for the same indication in July 2022 for individuals aged 12 and older.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2023 Category: Consumer Health News Tags: Dermatology News Source Type: news
Study Confirms Psoriasis Linked to Higher Heart Disease Risk Study Confirms Psoriasis Linked to Higher Heart Disease Risk
To date, the study is the largest to explore the relationship between severe psoriasis and coronary microvascular dysfunction.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 20, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Coronary Microvascular Dysfunction ID'd in 31.5 Percent With Psoriasis
WEDNESDAY, Sept. 20, 2023 -- Coronary microvascular dysfunction (CMD) occurs in 31.5 percent of patients with psoriasis, with disease severity and duration associated with increased risk, according to a study published in the October issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2023 Category: Pharmaceuticals Source Type: news
Study Confirms Psoriasis Linked to Higher Heart Disease Risk Study Confirms Psoriasis Linked to Higher Heart Disease Risk
To date, the study is the largest to explore the relationship between severe psoriasis and coronary microvascular dysfunction.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - September 20, 2023 Category: Internal Medicine Tags: Dermatology Clinical Summary Source Type: news
Link Between Psoriasis, Heart Disease Tracks to Coronary Microvascular Dysfunction
(MedPage Today) -- Almost a third of patients with severe psoriasis had echocardiographic evidence of asymptomatic coronary microvascular dysfunction (CMD), a prospective study showed.
Doppler echocardiography showed that 31.5% of 448 patients... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 20, 2023 Category: Cardiology Source Type: news
UCB Provides Update on U.S. Regulatory Review of Bimekizumab
Brussels (Belgium), 19 September 2023– UCB, a global biopharmaceutical company, today provided an update on the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis.
UCB has... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 19, 2023 Category: Drugs & Pharmacology Source Type: news
Association of psoriasis with depression, anxiety, and suicidality: a bidirectional two-sample Mendelian randomization study - Chu M, Shen S, Zhu Z, Li Z, Bai Y, Ma J, Hao J, Wang L, Fu M, Dang E, Wang G, Shao S.
Psoriasis is a chronic, refractory inflammatory skin disease, with a high prevalence of psychiatric comorbidities, including depression, anxiety, and even suicidality, which may in turn initiate or exacerbate skin inflammation. However, the causal relation... (Source: SafetyLit)
Source: SafetyLit - September 16, 2023 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
